{
    "nctId": "NCT03618810",
    "briefTitle": "Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer",
    "officialTitle": "The Effect, Safety and Pharmacoeconomics of First or Second Level-prophylactic Use of PEG-rhG-CSF in Breast Cancer Patients With Medium-high Risk of Febrile Neutropenia During Chemotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Febrile Neutropenia",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 2000,
    "primaryOutcomeMeasure": "FN rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. provision of informed consent\n2. stage I-III, invasive breast cancer\n3. accept at least 4 cycles of chemotherapy\n4. ECOG score 0-2\n5. with medium-high risk of FN according to researchers\n\nExclusion Criteria:\n\n1. accepted stem cell or bone marrow transplant\n2. undergoing any other clinical trial\n3. uncontrolled infection, temperature\u226538\u2103\n4. per-week scheme chemotherapy\n5. concurrent with radiotherapy\n6. allergic conditions\n7. sever organ dysfunction\n8. uncontrolled diabetes",
    "sex": "FEMALE",
    "minimumAge": "13 Years",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}